BioSpace News Archive

Sarepta Therapeutics, Inc. today announced that senior management will participate in fireside chats at two upcoming investor conferences.

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the fourth quarter 2023 on Thursday, March 21, 2024.

Masimo (NASDAQ: MASI) today announced that its management will participate in the 45th Annual Raymond James Institutional Investors Conference on Tuesday, March 5, 2024 at 3:25 p.m. Eastern Time.

Intelligent Scopes Corp, specializing in state-of-the-art image enhancement and precision AI software solutions for gastroenterology and urology, is pleased to announce the completion of its AI platform for gastroenterology, namely, Helga AI-GEP™.

The National Comprehensive Cancer Network® is announcing several new updates to the cancer treatment practices listed in the NCCN Clinical Practice Guidelines in Oncology.

A2 Biotherapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to A2B530 for the treatment of germline heterozygous HLA-A*02(+) patients with colorectal cancer that expresses carcinoembryonic antigen (CEA) and has lost HLA-A*02 expression.

NeurAxis, Inc., a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, announced receipt of Blue Cross and Blue Shield of Kansas City policy coverage for approximately one million lives.

Scilex Holding Company announced the launch of its redesigned website showcasing the Company’s growing portfolio of non-opioid pain management therapeutics.

Alumis Inc., a clinical stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, today announced two clinical data presentations at the American Academy of Dermatology Annual Meeting taking place March 8-12, 2024, in San Diego, CA.

Neurophet, an artificial intelligence (AI) solution company for brain disease, announced its participation in the international conference on Alzheimer’s and Parkinson’s diseases and related neurological disorders (AD/PD 2024).